Current Oncology Reports最新文献_第2页

Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma. 长链非编码rna在多发性骨髓瘤中的表观遗传作用。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01623-5

Nikita Mehra, Subhiksha Sundaram, Parth Shah, Arunagiri Kuha Deva Magendhra Rao

{"title":"Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma.","authors":"Nikita Mehra, Subhiksha Sundaram, Parth Shah, Arunagiri Kuha Deva Magendhra Rao","doi":"10.1007/s11912-024-01623-5","DOIUrl":"10.1007/s11912-024-01623-5","url":null,"abstract":"Purpose of the review: This review aims to explore the pivotal role of long non-coding RNAs (lncRNAs) as epigenetic regulators in the pathogenesis of multiple myeloma (MM). Additionally, we have portrayed the dual role of lncRNAs in the epigenetic landscape of MM pathobiology.Recent findings: In MM, lncRNAs are pivotal for proliferation, progression, and drug resistance by acting as miRNA sponges, regulating mRNA activity through microRNA recognition elements (MREs). Epigenetic modifications in lncRNAs influence gene expression, with some like MEG3, GAS5, CRNDE, and H19 showing promoter hypermethylation, while MALAT1 exhibits hypomethylation. Targeting lncRNAs using siRNA, ASO, CRISPR-Cas9, or small molecule inhibitors shows promise in preclinical studies, alongside the potential benefits of epigenetic-based therapies such as DNMTi and HDACi. Clinical trials combining epigenetic modifiers with standard chemotherapy show encouraging results, especially in relapsed/refractory MM. The key finding of the studies highlighted in the review paves the way for understanding the epigenetic role of lncRNAs in MM disease progression and biology. In addition, the novel therapeutic strategies that have shown promising results have been highlighted. The adoption of the epigenetic landscape into therapeutics in addition to existing treatment strategies may increase the efficacy of treatment approaches.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"37-44"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials. 微生物组和饮食对癌症检查点免疫治疗反应的作用：临床试验的叙述性回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01622-6

Lone Gamrath, Tobias Bruun Pedersen, Martin Vad Møller, Lone Marie Volmer, Linda Holst-Christensen, Lene Weber Vestermark, Frede Donskov

{"title":"Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials.","authors":"Lone Gamrath, Tobias Bruun Pedersen, Martin Vad Møller, Lone Marie Volmer, Linda Holst-Christensen, Lene Weber Vestermark, Frede Donskov","doi":"10.1007/s11912-024-01622-6","DOIUrl":"10.1007/s11912-024-01622-6","url":null,"abstract":"Purpose of review: The advent of checkpoint immunotherapy has dramatically changed the outcomes for patients with cancer. However, a considerable number of patients have little or no response to therapy. We review recent findings on the connection between the gut microbiota and the immune system, exploring whether this link could enhance the effectiveness of immunotherapy.Recent findings: Clinical studies have reported specific types of bacteria in larger quantities at baseline in responders than in non-responders, especially Akkermansia mucinifila, Ruminococcaceae, Faecalibacterium, and Lachnospiraceae. Following the consumption of a high-fiber diet, bacteria in the gut ferment dietary fiber to short-chain fatty acids (SCFAs), like acetate, propionate, and butyrate. Some of the SCFAs nurture intestinal epithelial cells, and some enter the bloodstream. Here SCFAs can activate DC8 + cytotoxic T-cells to induce cancer cell death. High fiber intake in the diet was associated with a reduced risk of progression or death during checkpoint immunotherapy. Recent findings demonstrate that high-fiber plant-based diets such as the Mediterranean Diet positively influence the gut microbiota whereas antibiotics and proton pump inhibitors can negatively influence outcomes of cancer immunotherapy by changing the gut microbiota. This narrative review provides evidence of an association between types of bacteria and their metabolites and favorable responses to checkpoint immunotherapy. Prospective clinical trials are needed to determine if diet interventions can improve treatment outcomes.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"45-58"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights. 人表皮生长因子受体2阳性晚期胃或食管胃腺癌：反思过去获得新的认识

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01626-2

Yu Aoki, Izuma Nakayama, Kohei Shitara

{"title":"Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.","authors":"Yu Aoki, Izuma Nakayama, Kohei Shitara","doi":"10.1007/s11912-024-01626-2","DOIUrl":"10.1007/s11912-024-01626-2","url":null,"abstract":"Purpose of review: Human epidermal growth factor receptor 2 (HER2) is a critical target in advanced gastric cancer (AGC). This review highlights the current treatment landscape, lessons learned from past clinical trials, and prospects for future treatment strategies for HER2-positive AGC.Recent findings: Trastuzumab had been the standard treatment for HER2-positive AGC for a decade, and subsequently, trastuzumab deruxtecan, an antibody-drug conjugate (ADC), emerged with an impressive response. Recently, the addition of pembrolizumab to first-line chemotherapy plus trastuzumab has become a novel standard treatment. Past clinical trials of HER2-targeted therapies, which succeeded in HER2-positive breast cancer but failed in AGC, have deepened our understanding of resistance mechanisms. Based on these results, several clinical trials of novel HER2-targeted therapies, including immunologic approaches such as CAR-T cells and vaccines, are currently ongoing. Circulating tumor DNA is also expected to be a tool for real-time biomarker analysis. Additionally, ADCs with a bystander effect have the potential to expand the scope of HER2-targeted therapies to HER2-expressing, including HER2-low AGC. Learning from past trials, further development of novel HER2-targeted therapies is underway, expanding their scope to HER2-expressing AGC. Meanwhile, selecting optimal treatment is a challenging issue in cases with HER2-low AGC overlapping with other biomarkers like CLDN18.2.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"15-29"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Developments in VHL-Associated Neuroendocrine Neoplasms. vhl相关神经内分泌肿瘤的新进展。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1007/s11912-024-01631-5

Marina Tsoli, Maria Panagaki, Elisavet Tasouli, Dionysia Kolomodi, Gregory Kaltsas

引用次数: 0

Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing. 乳腺癌中的抗体-药物偶联物：通往生物学知情选择和测序的道路。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1007/s11912-024-01628-0

Tess A O'Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C Garrido-Castro, Sara M Tolaney

{"title":"Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.","authors":"Tess A O'Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C Garrido-Castro, Sara M Tolaney","doi":"10.1007/s11912-024-01628-0","DOIUrl":"10.1007/s11912-024-01628-0","url":null,"abstract":"Purpose of review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.Recent findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures. In this new frontier, translational efforts are underway to personalize the use of ADCs, including refining HER2 quantification and elucidating genetic, epigenetic, and post-translational mechanisms of resistance. ADCs have provided important treatment options for patients with breast cancer. As patients become eligible for more than one ADC, there is an unmet need to identify the appropriate timing and sequence of these therapies to maximize their efficacy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"68-79"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors. 多学科治疗局部胃食管交界处肿瘤的当前标准和争议。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1007/s11912-024-01606-6

Emily T Santos, Deenah Baig, Nina N Sanford

{"title":"Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors.","authors":"Emily T Santos, Deenah Baig, Nina N Sanford","doi":"10.1007/s11912-024-01606-6","DOIUrl":"10.1007/s11912-024-01606-6","url":null,"abstract":"Purpose of review: There has been controversy in the management of gastroesophageal (GE) junction cancers with pre-operative chemoradiation and peri-operative chemotherapy as accepted practices. We aim to assess and compare the defining trials establishing current standards of care and discuss future directions seeking to further improve patient-centered outcomes in GE junction cancers.Recent findings: Over the last two decades, several large Phase III randomized trials have been conducted including GE junction cancers, showing superiority of 1) pre-operative chemoradiation over surgery (CROSS) and 2) peri-operative chemotherapy with FLOT over CROSS without radiotherapy (FLOT 4). While NEO-Aegis suggested equipoise between the CROSS vs. peri-operative chemotherapy, the recently presented ESOPEC trial demonstrated superiority of peri-operative FLOT versus CROSS in esophagus and GE junction adenocarcinomas. Based on the ESOPEC trial, peri-operative chemotherapy with FLOT appears to be a preferred regimen for patients with resectable GE junction adenocarcinomas in patients able to receive FLOT. There is evidence in support of other practices, such as induction chemotherapy, pre-operative chemoradiation, definitive chemoradiation for those not fitting ESOPEC criteria. Chemoradiation ± chemotherapy with non-operative intent represents a promising strategy for patients seeking organ preservation, and ongoing studies will better define its feasibility and long-term outcomes.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1606-1611"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review. 治疗常见癌症脑转移的免疫治疗和靶向策略：最新研究综述》。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-08 DOI: 10.1007/s11912-024-01593-8

Vivek Podder, Shreyas Bellur, Kim Margolin, Pooja Advani, Reshma L Mahtani, Vivek Subbiah, Gabriella B Novo, Tulika Ranjan, Manmeet S Ahluwalia

{"title":"Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review.","authors":"Vivek Podder, Shreyas Bellur, Kim Margolin, Pooja Advani, Reshma L Mahtani, Vivek Subbiah, Gabriella B Novo, Tulika Ranjan, Manmeet S Ahluwalia","doi":"10.1007/s11912-024-01593-8","DOIUrl":"10.1007/s11912-024-01593-8","url":null,"abstract":"Purpose of review: This review examines contemporary strategies for managing brain metastases (BM) from common cancers such as lung, breast, and melanoma. We evaluate the efficacy and applicability of targeted therapies and immunotherapies, exploring their potential to cross the blood-brain barrier and improve patient outcomes.Recent findings: Recent studies have shown that tyrosine kinase inhibitors, immune checkpoint inhibitors, and ADCs effectively treat BM. These treatments can overcome the challenges posed by the blood-brain barrier and improve therapeutic outcomes. ADCs are promising because they can deliver cytotoxic agents directly to tumor cells, which reduces systemic toxicity and increases drug delivery efficiency to the brain. Personalized medicine is becoming increasingly significant in treatment decisions, with biomarkers playing an essential role. Advances in molecular genetics and drug development have led to more refined treatments, emphasizing the precision medicine framework. The management of BM is evolving, driven by drug efficacy, resistance mechanisms, and the need for personalized medicine. Integrating ADCs into treatment regimens represents a significant advancement in targeting metastatic brain tumors. Despite these advances, BM management still presents considerable challenges, requiring ongoing research and multi-institutional trials to optimize therapeutic strategies. This review outlines the current state and future directions in treating BM, highlighting the critical need for continued innovation and comprehensive clinical evaluations to improve survival rates and quality of life for affected patients.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1612-1638"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review. 平衡青少年和年轻成人乳腺癌患者（新）辅助治疗中的生育力保护和治疗效果：叙述性综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-05 DOI: 10.1007/s11912-024-01615-5

Yuji Tanaka, Tsukuru Amano, Akiko Nakamura, Akimasa Takahashi, Akie Takebayashi, Tetsuro Hanada, Shunichiro Tsuji, Takashi Murakami

{"title":"Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review.","authors":"Yuji Tanaka, Tsukuru Amano, Akiko Nakamura, Akimasa Takahashi, Akie Takebayashi, Tetsuro Hanada, Shunichiro Tsuji, Takashi Murakami","doi":"10.1007/s11912-024-01615-5","DOIUrl":"10.1007/s11912-024-01615-5","url":null,"abstract":"Purpose of review: Adolescent and young adult (AYA) breast cancer survivors face a significant risk of infertility due to the gonadotoxic effects of (neo)adjuvant therapy, which complicates their ability to conceive post-treatment. While (neo)adjuvant therapy primarily aims to improve recurrence-free and overall survival, fertility preservation strategies should also be considered for young patients. This narrative review explores recent advancements in fertility preservation techniques, such as oocyte, embryo, and ovarian tissue cryopreservation, and evaluates the feasibility of modifying breast cancer (neo)adjuvant therapy to preserve fertility without compromising survival outcomes.Recent findings: Our review highlights that clinical trials with co-primary endpoints of oncological safety and fertility preservation are limited, and substituting standard treatment regimens solely for fertility preservation is currently not recommended. Nevertheless, new clinical studies have emerged that either exclude highly ovarian-toxic agents, such as cyclophosphamide, or omit adjuvant therapy altogether, even if fertility preservation is not their primary endpoint. Unfortunately, many of these trials have not evaluated ovarian toxicity. Notably, since 2020, major oncology organizations, including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) have advocated for the routine assessment of ovarian toxicity in all clinical trials. The review underscores the importance of incorporating ovarian toxicity as a standard endpoint in future trials involving premenopausal breast cancer patients to identify treatment regimens that can effectively balance fertility preservation with treatment efficacy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1563-1574"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telemedicine and Virtual Interventions in Cancer Rehabilitation: Practical Application, Complications and Future Potentials. 癌症康复中的远程医疗和虚拟干预：癌症康复中的远程医疗和虚拟干预：实际应用、并发症和未来潜力》。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1007/s11912-024-01612-8

Philip Chang, Jessica Engle

引用次数: 0

Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations. 乳腺癌治疗与生育力保护：影响、策略和伦理考虑的叙述性回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1007/s11912-024-01619-1

Prakriti Anuj Sachdev, Natalie George Ayad, Constantina Constantinou

{"title":"Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations.","authors":"Prakriti Anuj Sachdev, Natalie George Ayad, Constantina Constantinou","doi":"10.1007/s11912-024-01619-1","DOIUrl":"10.1007/s11912-024-01619-1","url":null,"abstract":"Purpose of review: At present, breast cancer represents the most common malignancy diagnosed in women worldwide. Due to the trend toward delayed childbearing, many women of reproductive age are being diagnosed with breast cancer and treated with chemotherapy or hormone therapy which can adversely affect their fertility. This literature review discusses the effects of breast cancer treatment on fertility and options for fertility preservation.Recent findings: Treatments used in the management of breast cancer often result in a diminished ovarian reserve, premature ovarian insufficiency, and treatment-related amenorrhea. Chemotherapy may cause direct damage to oocytes and deplete ovarian reserve, while hormone therapies such as tamoxifen can cause amenorrhea and delay childbearing. Targeted therapies and radiotherapy may also pose risks to reproductive health. Fertility preservation is a concern for patients, and many of them may refuse or prematurely discontinue treatment to preserve their fertility. It is relevant to incorporate considerations of fertility at the time of treatment planning for breast cancers and to provide information to appropriate patients regarding their options. Current techniques available for fertility preservation include ovarian suppression, oocyte and embryo cryopreservation, and ovarian tissue cryopreservation. In spite of these techniques being in existence, there are plenty of barriers that deter the patients from availing them, including lack of awareness, financial constraints, and the need for timely treatment. This review implicates that these challenges require multidisciplinary approaches and a patient-centered approach. Further research is warranted toward the improvement of fertility preservation techniques, individual variability in protocols, and newer advances in reproductive medicine to further optimize quality of life in survivors of breast cancer.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1575-1585"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0